Dapiglutide is an investigational long-acting dual GLP-1/GLP-2 receptor agonist developed for obesity. A 2026 Phase IIa study did not show a statistically significant difference in body-weight change versus placebo at the tested doses, and the development program is currently paused.

GLP-1 vs GLP-2: What’s the Difference—and Could GLP-2 Be the Next Weight-Loss Breakthrough?

Q: Could GLP-1 and GLP-2 eventually be combined?

Yes. Dapiglutide demonstrates that dual GLP-1/GLP-2 receptor activation is pharmacologically possible. Whether it produces enough additional clinical benefit remains an open research question.

GLP-1 vs GLP-2: What’s the Difference—and Could GLP-2 Be the Next Weight-Loss Breakthrough?

- September 20, 2026

GLP-1 vs GLP-2: Both are glucagon-like peptides made from the same proglucagon precursor, but they are not interchangeable hormones. GLP-1 has become a major metabolic drug target because it can reduce appetite, improve glucose control and promote weight loss. GLP-2 is much more strongly associated with intestinal growth, nutrient absorption, barrier function and adaptation. That difference is now attracting attention as researchers explore whether combining GLP-1 and GLP-2 receptor activity could create a new approach to obesity and metabolic disease.

Bottom line: GLP-1 is primarily a metabolic and appetite-regulating signal; GLP-2 is primarily an intestinal growth and adaptation signal. GLP-2 is not simply a stronger or newer version of GLP-1. The two hormones have distinct receptors, biological actions and established clinical applications.

Updated: September 20, 2026

In this guide

What are GLP-1 and GLP-2?
GLP-1 vs GLP-2: side-by-side comparison
How GLP-1 affects appetite, glucose and weight
How GLP-2 affects the intestine
GLP-1 drugs vs GLP-2 drugs
Why GLP-2 is being studied in obesity
What happened with dapiglutide?
GLP-1/GLP-2 dual agonists: promise and limitations
Safety and unanswered questions
Frequently asked questions

What Are GLP-1 and GLP-2?

GLP-1 and GLP-2 are peptide hormones derived from the same proglucagon precursor. In intestinal enteroendocrine L cells, proglucagon is processed into several peptides, including GLP-1 and GLP-2. They are therefore biologically related, but their actions diverge because GLP-1 and GLP-2 activate different receptors: the GLP-1 receptor (GLP-1R) and the GLP-2 receptor (GLP-2R). Review article on GLP-1 and GLP-2.

This distinction matters because the extraordinary success of GLP-1-based medicines in obesity has created interest in other hormones produced by the same intestinal L cells. GLP-2 is one of the most important examples.

But the biology is different. GLP-1 helps coordinate what happens after nutrients are absorbed by influencing insulin, glucagon, gastric emptying and food intake. GLP-2 is much more focused on what happens inside the intestine itself, helping regulate mucosal growth, digestion, absorption, barrier function and intestinal adaptation. GLP-2 review in Comprehensive Physiology.

GLP-1 vs GLP-2: Side-by-Side

Feature	GLP-1	GLP-2
Origin	Primarily intestinal L cells; also related proglucagon pathways in the nervous system	Primarily intestinal L cells
Primary receptor	GLP-1R	GLP-2R
Main biological emphasis	Glucose regulation, appetite and gastrointestinal motility	Intestinal growth, adaptation, absorption and barrier function
Insulin	Increases glucose-dependent insulin secretion	Not its defining clinical action
Glucagon	Suppresses glucagon secretion in a glucose-dependent context	Not its defining clinical action
Appetite	Reduces food intake and increases satiety	Not primarily an appetite hormone
Gastric emptying	Slows gastric emptying	Can affect gastrointestinal function, but the therapeutic focus is intestinal adaptation
Intestinal mucosa	Indirect and context-dependent effects	Major target: supports mucosal growth, repair and absorptive capacity
Clinical role today	Major treatment platform for type 2 diabetes and obesity	Established drug class mainly for short bowel syndrome / intestinal failure
Representative medicine	Semaglutide; liraglutide; other GLP-1-based therapies	Teduglutide, a GLP-2 analogue
Primary weight-loss role	Established	Investigational rather than an established indication

How GLP-1 Works

GLP-1 is best known as an incretin hormone. After nutrient intake, GLP-1 contributes to the glucose-dependent stimulation of pancreatic insulin secretion while suppressing glucagon. It also slows aspects of gastric emptying and participates in the regulation of appetite and food intake. These combined effects helped turn GLP-1 receptor agonists into powerful therapies for type 2 diabetes and obesity. GLP-1 physiology and obesity pharmacotherapy review.

Modern GLP-1 medicines extend the signal far beyond the short physiological exposure of endogenous GLP-1. Long-acting receptor agonists can maintain pharmacological activity long enough to produce sustained reductions in food intake and body weight.

GLP-1 and Weight Loss

The weight-loss effect of GLP-1 receptor agonism is driven largely by a reduction in energy intake. In the landmark STEP 1 obesity trial, once-weekly semaglutide 2.4 mg combined with lifestyle intervention produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo. Nausea and diarrhea were among the most common adverse events. Wilding et al., NEJM, 2021.

That result illustrates why GLP-1 has become the dominant hormone pathway in the current obesity-drug era: the biology is well established, the medicines are clinically validated, and the weight-loss signal is substantial.

How GLP-2 Works

GLP-2 is different. Its best-characterized biological role is the maintenance and adaptation of the intestinal tract.

GLP-2 signalling can promote intestinal epithelial growth, increase absorptive capacity, support mucosal integrity and influence intestinal blood flow and barrier function. These actions are particularly important when the intestine has lost substantial absorptive surface area, as occurs in short bowel syndrome. Drucker & colleagues: GLP-2 and intestinal growth and function.

In other words, GLP-2 is less about telling the brain “eat less” and more about helping the gut “adapt, absorb and maintain its lining.”

GLP-2 and the Gut Barrier

The intestinal epithelium is not merely a passive surface. It is a dynamic barrier that separates the gut lumen from the internal environment while allowing selective nutrient absorption. GLP-2 signalling participates in this system and has been shown to enhance barrier function and cytoprotective pathways in experimental models and to produce intestinal benefits in humans with intestinal failure. Physiology and pharmacology of GLP-2.

This gut-barrier biology is one reason GLP-2 has attracted attention beyond short bowel syndrome. However, the existence of a plausible mechanism does not establish that a GLP-2 medicine will improve inflammation, cardiovascular disease, fatty liver disease or other obesity-related conditions in clinical practice.

GLP-1 Drugs vs GLP-2 Drugs

GLP-1-Based Medicines

GLP-1 receptor agonists are now established medical treatments for metabolic disease. Examples include semaglutide and liraglutide. Some newer medicines activate GLP-1 together with another receptor, such as GIP, but that is a different pharmacological strategy from combining GLP-1 and GLP-2.

For example, the FDA prescribing information for Ozempic identifies semaglutide as a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and for certain cardiovascular and kidney risk-reduction indications in specified populations. FDA Ozempic prescribing information.

GLP-2-Based Medicines

The best-established GLP-2 medicine is teduglutide, a long-acting GLP-2 analogue. In the United States, GATTEX (teduglutide) is indicated for adults and pediatric patients aged 1 year and older with short bowel syndrome who are dependent on parenteral support. Its purpose is to improve intestinal absorption of fluids and nutrients and reduce dependence on parenteral support. FDA orphan-drug listing for GATTEX and FDA GATTEX label.

That is a fundamentally different therapeutic objective from obesity treatment.

Why Is GLP-2 Being Studied for Obesity?

The hypothesis is not that GLP-2 itself should replace GLP-1. Instead, researchers have asked whether adding GLP-2 biology to GLP-1 biology could create advantages that GLP-1 alone does not provide.

Obesity is associated with metabolic dysfunction, altered intestinal physiology and chronic low-grade inflammation. Because GLP-2 can influence the intestinal barrier and mucosal environment, developers have proposed that GLP-2 agonism could provide complementary effects alongside GLP-1-mediated weight loss.

That is a reasonable biological hypothesis, but it remains a hypothesis. A mechanistic rationale is not the same thing as a demonstrated clinical benefit.

Dapiglutide: The Leading Example of GLP-1/GLP-2 Dual Agonism

Dapiglutide is an investigational long-acting dual GLP-1R/GLP-2R agonist developed for obesity. The concept was designed to combine the weight-loss effects associated with GLP-1 receptor activity with potential intestinal and barrier-related effects associated with GLP-2 receptor activity.

Early studies generated interest, including a 2025 Phase 1b report from Zealand Pharma describing placebo-adjusted weight loss with higher doses over 28 weeks. However, small early-stage studies are not sufficient to establish clinical efficacy or long-term safety.

More importantly, the development story subsequently changed. A 2026 randomized Phase IIa proof-of-concept trial evaluated 4 mg and 6 mg dapiglutide for 12 weeks in 54 adults with obesity and found that the 6 mg group had a mean body-weight change of −2.1% versus placebo, with p=0.076. The investigators concluded that neither dose produced a statistically significant difference from placebo over the 12-week treatment period. Nielsen et al., EClinicalMedicine, 2026.

At the company level, Zealand Pharma now lists dapiglutide as a paused program and states that further development was paused as part of active portfolio management. The company's current pipeline describes the program as Phase 2-ready but development-paused. Zealand Pharma: Dapiglutide program paused.

Important: Dapiglutide is investigational. It is not an approved obesity treatment. Early weight-loss signals should not be interpreted as evidence that GLP-1/GLP-2 dual agonism is superior to established GLP-1-based therapy.

What Does Dapiglutide Tell Us About GLP-2?

The dapiglutide story is useful precisely because it highlights the difference between biological plausibility and clinical validation.

The concept is biologically coherent:

GLP-1 receptor activity can reduce food intake and body weight.
GLP-2 receptor activity can support intestinal mucosal adaptation and barrier function.
A single molecule could, in principle, engage both pathways.

But a clinical drug must demonstrate that those pathways produce meaningful benefits in actual patients, at doses that are effective and tolerable, over an adequate duration and with acceptable long-term safety.

The 2026 Phase IIa trial therefore matters. It did not prove that the biological concept is wrong; it showed that the tested 4 mg and 6 mg regimens did not deliver a statistically significant weight-loss advantage over placebo in that 12-week trial. PubMed: dapiglutide Phase IIa.

GLP-1/GLP-2 vs GLP-1/GIP: Don't Confuse the Two

The rapidly expanding obesity-drug landscape contains several different dual-agonist strategies, and the names can be confusing.

Strategy	Primary concept	Example	Development status / role
GLP-1	Appetite reduction, glucose control, gastrointestinal effects	Semaglutide	Established clinical therapy
GLP-1 + GIP	Combines two incretin pathways for metabolic and weight effects	Tirzepatide	Established clinical therapy
GLP-1 + GLP-2	Adds intestinal GLP-2 biology to GLP-1-mediated weight-loss biology	Dapiglutide	Investigational; dapiglutide program currently paused
GLP-1 + glucagon	Combines appetite/metabolic effects with glucagon-mediated energy and liver pathways	Survodutide	Investigational
Triple or multi-agonist approaches	Attempts to combine several metabolic signals in one molecule	Multiple candidates in development	Emerging research field

The fact that a molecule targets two receptors does not automatically make it more effective. Each combination must be judged on its own pharmacology, dose, trial design, efficacy, tolerability and long-term outcomes.

Could GLP-2 Improve the “Quality” of Weight Loss?

This is one of the more interesting questions for future research, but it should not be presented as established fact.

One theoretical attraction of GLP-2 is that it acts on the intestine rather than simply adding another appetite-suppressing signal. Researchers have proposed potential effects on intestinal integrity, nutrient handling and inflammation. A successful GLP-1/GLP-2 medicine might therefore aim to do more than reduce the number on the scale.

But there are several unanswered questions:

Does GLP-2 meaningfully improve obesity-associated inflammation in humans?
Does dual agonism produce an outcome that is clinically superior to GLP-1 or GLP-1/GIP therapy?
Does GLP-2 alter body-composition changes during weight loss?
Are there long-term intestinal consequences of sustained GLP-2 receptor stimulation?
Which obesity-related comorbidities, if any, respond specifically to the GLP-2 component?

These questions require dedicated clinical trials rather than extrapolation from physiology.

GLP-2 Safety: An Important Difference

Because GLP-2 promotes intestinal growth and adaptation, its pharmacology raises safety considerations that are not identical to those of conventional GLP-1 therapy.

The FDA materials for teduglutide describe concerns including the potential for accelerated neoplastic growth and enhancement of gastrointestinal polyp growth, as well as gastrointestinal obstruction, biliary and pancreatic disorders, fluid-related complications and altered absorption of concomitant oral medications. These risks and monitoring requirements are specific to teduglutide and should not automatically be transferred to every future GLP-2-containing drug, but they illustrate why chronic GLP-2 receptor stimulation requires careful safety evaluation. FDA GATTEX review.

Clinical caution: A GLP-2 analogue should not be treated as a nutritional supplement or as a general-purpose “gut healing” product. Teduglutide is a prescription biologic drug used for a specific intestinal-failure indication and has important safety monitoring requirements.

Is GLP-2 a Weight-Loss Hormone?

Not in the same sense as GLP-1.

GLP-2 has been studied in obesity because researchers are interested in the intestine as a therapeutic target, not because GLP-2 has become an established appetite-suppressing hormone. The current evidence base supports a strong intestinal role for GLP-2. Evidence that isolated GLP-2 receptor agonism should be used as a standard weight-loss treatment is much weaker.

Dapiglutide is a good illustration. It was designed as a dual GLP-1/GLP-2 drug rather than a pure GLP-2 weight-loss drug, precisely because the developers wanted the established weight-loss biology of GLP-1 together with additional GLP-2 pharmacology.

GLP-1 vs GLP-2: Which Pathway Matters More?

There is no scientifically useful universal answer because the two hormones solve different physiological problems.

For appetite suppression, glucose lowering and established obesity pharmacotherapy, GLP-1 is the better-established pathway.

For intestinal adaptation, mucosal growth, absorptive capacity and short bowel syndrome, GLP-2 is the clinically relevant pathway.

The more interesting question for next-generation metabolic medicines is whether these distinct actions can be combined without creating unacceptable trade-offs.

The Bigger GLP Story: From Single Hormones to Multi-Agonists

The pharmaceutical industry is moving from simple single-receptor strategies toward molecules that activate multiple hormonal pathways. GLP-1/GIP is already clinically important, while GLP-1/glucagon and other combinations remain under active development.

GLP-1/GLP-2 occupies a different niche because the second receptor is associated much more strongly with the intestine. That creates a potentially attractive research question: can metabolic therapy and intestinal biology be deliberately integrated into the same medicine?

For now, however, GLP-1/GLP-2 remains an experimental concept rather than an established next-generation obesity standard. The current dapiglutide program status makes that especially clear. Zealand Pharma pipeline.

Frequently Asked Questions

Is GLP-2 the same as GLP-1?

No. They are different peptides produced from the same proglucagon precursor and primarily released from intestinal L cells, but they activate different receptors and perform different physiological functions. PubMed review.

Does GLP-2 cause weight loss?

GLP-2 is not an established weight-loss treatment. Its best-established clinical role is intestinal adaptation and improved absorption in short bowel syndrome. Researchers have explored GLP-2-containing molecules for obesity, but this remains investigational.

What is the main difference between GLP-1 and GLP-2?

GLP-1 mainly regulates glucose handling, appetite and gastrointestinal motility, whereas GLP-2 primarily supports intestinal growth, absorption, barrier function and adaptation.

What drug activates GLP-2?

Teduglutide is a long-acting GLP-2 analogue approved in the United States for patients with short bowel syndrome who are dependent on parenteral support. FDA.

What is dapiglutide?

Dapiglutide is an investigational long-acting dual GLP-1/GLP-2 receptor agonist developed for obesity. A 2026 Phase IIa study of 4 mg and 6 mg doses over 12 weeks did not show a statistically significant difference in body-weight change versus placebo. The developer currently lists the program as paused. PubMed; Zealand Pharma.

Could GLP-1 and GLP-2 eventually be combined?

Yes. Dapiglutide demonstrates that this is pharmacologically possible. The unresolved issue is whether dual GLP-1/GLP-2 activation produces enough additional clinical benefit to justify the added complexity and long-term safety considerations.

Is GLP-2 better than GLP-1 for gut health?

That comparison is too broad. GLP-2 has a much more direct and established role in intestinal growth and adaptation, whereas GLP-1 has important gastrointestinal effects but is primarily used therapeutically for metabolic disease. “Gut health” is also a broad term that should not be treated as a single clinical endpoint.

Key Takeaways

GLP-1 and GLP-2 come from the same proglucagon precursor but have different receptors and biological functions.
GLP-1 is the established metabolic pathway for appetite reduction, glucose control and obesity pharmacotherapy.
GLP-2 is primarily an intestinal growth and adaptation hormone.
Teduglutide is an established GLP-2 medicine for short bowel syndrome, not a general weight-loss drug.
GLP-1/GLP-2 dual agonism is an emerging research strategy rather than an established clinical category.
Dapiglutide provides an important real-world test of the concept: its 2026 Phase IIa obesity trial did not show statistically significant weight loss versus placebo at the tested doses, and the development program is now paused.
The future question is not whether GLP-2 can replace GLP-1, but whether targeted GLP-2 biology can add clinically meaningful benefits to next-generation metabolic therapies.

Evidence & Sources

Medical information disclaimer: This article is for educational purposes only and is not personal medical advice. Drug indications, regulatory status and clinical evidence can change. Investigational medicines should not be used outside appropriate clinical research or medical supervision.